A LONG-TERM DOUBLE-BLIND COMPARISON OF DOXAZOSIN AND ATENOLOL IN PATIENTS WITH MILD TO MODERATE ESSENTIAL-HYPERTENSION
A LONG-TERM DOUBLE-BLIND COMPARISON OF DOXAZOSIN AND ATENOLOL IN PATIENTS WITH MILD TO MODERATE ESSENTIAL-HYPERTENSION
复制标题
DOI：
10.1111/j.1365-2125.1986.tb02854.x
复制
发表时间：
1986-01-01
影响因子：
3.4
通讯作者：
SARASTE, M
中科院分区：
文献类型：
--
作者：
FRICK, MH;HALTTUNEN, P;SARASTE, M
多沙唑嗪和阿替洛尔每日一次给药长达1年，至少20周的活性治疗后，比较了多沙唑嗪和阿替洛尔的疗效和安全性。根据缓解情况，患者接受多沙唑嗪1 - 16 mg（第1天）或阿替洛尔50 - 100 mg（第1天）。最终疗效评估时（20周至1年）的平均日剂量为多沙唑嗪11.8 mg和阿替洛尔94.2 mg。阿替洛尔使血压福尔斯的幅度略大于多沙唑嗪。仰卧位时差异具有统计学意义，但站立位时差异不显着。多沙唑嗪可使心率平均小幅降低，而阿替洛尔可使心率明显减慢。在20周时对同一患者组的分析显示，除了阿替洛尔产生的血压福尔斯幅度大于长期分析外，总体活性特征相似。多沙唑嗪治疗组血清HDL/总胆固醇比值升高，阿替洛尔组降低。多沙唑嗪组甘油三酯浓度下降，阿替洛尔组升高。治疗组之间观察到这些参数的显著差异（P <0.001），所有差异均有利于多沙唑嗪。在36例患者中稳态时测量的多沙唑嗪药代动力学显示剂量相关血浆浓度，平均半衰期约为12小时，受试者间变异相对较低。多沙唑嗪组患者的副作用发生率略高。药物相关副作用的严重程度大多为轻度至中度，两个治疗组均未发生严重药物相关事件。在两个治疗组中均未观察到实验室生化和血液学检查的严重药物相关异常。
The efficacy and safety of doxazosin and atenolol were compared following once‐daily administration for up to 1 year, with a minimum of 20 weeks' active treatment. According to response, patients received doxazosin 1‐16 mg day‐1 or atenolol 50‐100 mg day‐1. Mean daily doses at the final efficacy assessment (between 20 weeks and 1 year) were doxazosin 11.8 mg and atenolol 94.2 mg. Atenolol produced somewhat greater falls in blood pressure than doxazosin. The differences were statistically significant in the supine but not in the standing position. A small mean reduction in heart rate was produced by doxazosin whereas atenolol produced a marked bradycardia. Analysis of the same patient group at 20 weeks revealed similar overall profiles of activity except that atenolol produced greater falls in blood pressure than in the longer term analysis. Serum concentrations of HDL/total cholesterol ratio were raised in the doxazosin treatment group and lowered in the atenolol group. Triglyceride concentrations fell in the doxazosin group and rose in the atenolol group. Significant differences (P less than 0.001) were observed between treatment groups for these parameters, all differences being in favour of doxazosin. Pharmacokinetics of doxazosin, measured at steady state in 36 patients, showed dose‐related plasma concentrations, a mean half‐life of about 12 h and relatively low intersubject variation. The incidence of side‐ effects was slightly greater for patients in the doxazosin group. Drug‐ related side‐effects were mostly mild to moderate in severity with no serious drug‐related occurrences in either treatment group. No serious drug‐related abnormalities in laboratory biochemistry and haematology tests were observed in either treatment group.